Li-ru He

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3

Mengzhong Liu, Y. Zeng, Qiaoqiao Li, 2012, Journal of Translational Medicine.

b -Catenin/POU5F1/SOX2 Transcription Factor Complex Mediates IGF-I Receptor Signaling and Predicts Poor Prognosis in Lung Adenocarcinoma

You-hong Cui, X. Bian, Y. Ping, 2013 .

Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma

Mengzhong Liu, Y. Zeng, Hai-xia Deng, 2009, Cancer science.

Prognosticators and Risk Grouping in Patients with Lung Metastasis from Nasopharyngeal Carcinoma: A more accurate and appropriate assessment of prognosis

Z. Wen, R. Luo, Youfang Chen, 2011, Radiation oncology.

Polymorphisms of insulin-like growth factor binding protein-3 as a predictor for risk and patient survival in esophageal squamous cell carcinoma.

Mengzhong Liu, Qiaoqiao Li, M. Xi, 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin

Mengzhong Liu, Y. Zeng, Qiaoqiao Li, 2012, Tumor Biology.

Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma

Mengzhong Liu, Y. Zeng, M. Xi, 2012, Medical Oncology.

PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway

F. Zhou, Y. Zeng, Y-X Zeng, 2013, Molecular Cancer.

The telomere/telomerase binding factor PinX1 regulates paclitaxel sensitivity depending on spindle assembly checkpoint in human cervical squamous cell carcinomas.

Y. Zeng, D. Xie, H. Kung, 2014, Cancer letters.

Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients.

X. Bian, Y-X Zeng, D. Xie, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.